showed between 1953 and 1956 that allogeneic spleen and bone marrow (BM) cells induce tolerance when they are not rejected by the incompletely developed immune system of neonatal mouse recipients, and that the tolerance extends to donor strain skin Thomas E. Starzl and Rolf M. Zinkernagel Although transplantatio, immuno logy as a distinctive field began w h the development of experimental models thaI showed the feasibility of bone marrow I ansplantation, organ engraftment was accomplished first In humans, and was thought for many years to occur by drastically different mechanisms. Here . we present cur lJiew 0 he concepts of allograft acceptance and acquired tolerance from a historical perspective, and attempl to amalgamate them i to simple and unifying rules that might guide improvements in clinical therapy.
Our paradigm of transplantation immunology (reviewed in REF. I) had its origin in the nineteenth century. After the cellular, humoral and complement constituents of the immune response were discovered (see TlMW :\E), evidence emerged that an immune reaction was responsible for the failure of transplanted tissue and most tumour allografts to survive indefinitely". "''hen transplantation research declined during and after the First World War, these early accomplishments faded . Similarly, the significance of the :\EO" .• r.~L TO LER.'''CE shown in tumour and viral-infection models was not fully appreciated until Burnet's formulation of the tolerance and OO:vJ.-SELECTIO. hypothesis'. Finally, the phenomenon of 1~1~1l:" E IC:\Of(A :\CE was first shown in 1934 (REF. 4 ), but discounted until its rediscovery many years later-;. 6 .
The immunological basis of rejection
Modern transplantation immunology is often dated to the experiments by Medawar in 1944, which showed that skin allograft rejection is a HOST-\'ERSl'S -GR..FT (HVG) response', the cellmed iated features of wh ich were later defined by Mitchison 8 The term maior histocompatibility complex (MHC) was introduced by Gorer, Lyman and Snel1 9 for the genetic locus that encodes antigens associated ",>ith allograft rejection, tumour surveillance and other expressions of cell-mediated immunity. The MHC-restricted mechanisms ofT-cell recognition of, and response to, antigens, viruses and other intracellular microorgan. isms were elucidated in the 1970s (reviewed in REF. 10 ). n the sixth case of kidney transplantation, a renal allograft from a non-related donor functioned for 17 months after its translliantation under azathioprine-based therap/;, At first, the results \, 'th drug therapy were no better than with TBI. However, when la rge doses of predniso ne were added to azathio · prine in resllon e to c1in i 'ally diagno, ed rejections, two key observations were made, as described in the titl" 0f a rLtJort of ten cast's: "The reversal of rejection in human renal homografts with subsequent development of homograft tolerance"!" . The partial toleran referre d to the time-related diminution of dependence on immun05u ppression, which eventually was stollped"" in two of the llatients whose grafts still function after 39 Y MS . Frey and Wenk showed that no immune response is induced by otherwise sensitizing chemicals if the antigen is prevented from migrating to draining lymph nodes or spleen, an observation su bsequently extended to skin allografts by Barker and Billingham;. The second feature of the Stone proced ure became apparent with the demonstration by Lafferty and co-workers 6 that tissue culture comparable with that used 4 decades earlier in the parathyroid experiments depletes endocrine tissue of passenger leukocytes that are capable of migrating to host lymphoid organs. Similarly, allografts lose immunogenicity when their passenger leukocytes are removed from tissues or organs in 'parking experiments':lS-lC or by other means. The analogies between th e adaptive immune response or non-response (dashed lines) induced by the antigen of non-cytopathic microorganisms (M) and the analogous migratory leukocytes (l ) of allografts (solid lines) have been obscured by the presence of contemporaneous hostversus-graft (HVG ) and graft-versus-host (GVH) responses after transplantation and the additional factor of therapeutic immunosuppression. Under circumstances of both infection and transplantation, the immune response or non-response is regulated mainly by the migration and localization of the antigen. a I If the antigen fails to reach organized host lymphoid tissue, as occurs with the extralymphatic spread of an infection (for example, the human papilloma (wart) virus), there is no immune response (immune ignorance). Similarly, avoidance of host lymphoid organs by transplanting tissue to privileged sites or by depleting the allograft of passenger leukocytes might allow prolonged survival of'Stone-Lafferty' transplants, without evolution of donor-specific non-reactivity providing the mobile antigen (l) remains extralymphatic. Rejection of the graft can often be precipitated by leakage of graft cells in to the blood or lymph circulation (for example, after an infection or trauma" or an immuniz. ing injection of donor cells6.2' 1. b I Illustrates the immWle elimination of a spreading non-cytopathic microorganism that has reached host lymphoid organs and induced an antjgenspecific response. The outcome is comparable with the rejection of an outlying organ after its passenger leukocytes migrate to host lymphoid organs and jnduce an anti-donor response. After complete removal of the antigen, the immune response subsides. c I Depicts how the persistence of mobile live antigen that has access to host lymphoid organs can exhaust and delete the antigen-specific immune response. With infection, this might result in a stable carrier sta te (for example, the viral hepatitides, or lymphocytic choriomeningitis virus infestation). The transplant analogy is 'complete' repopulation of a recipient by donor bone marrow (BM)-derived cells after pure stem-cell transplantation to a severe combined immune deficiency (SCID) mouse, or after the less complete replacement (macrochimerism) with clinical BM transplantation to a host whose immWle response is weakened in advance by cytoablation or cytoreduction. This kind of tolerance in organ recipients is most often associated with macrochimerism'·'. d I Represents the acute control of an infection by incomplete elimination of microorganisms, resulting in cellular plus an tibody 'memory' sustained by the residual live antigen (for example, herpesvirus). In the transplantat ion analogy, partial deIetional tolerance induced at the outset under immunosuppression might be sustained by the residual donor cells (microchimerism ) with, or sometimes without, the aid of immWlosuppression. e I Shows more complete elimination of mkroorganisms than in Cd) with ' memory' (for example, tuberculosis or measles). In the transplantation analogy, survival of the minority population ofleukocytes requires continuous immunosuppression . f I Illustrates the survival of a large quantjty of microorganisms despite a strong persistent immune response, resulting in acute-chronic infection and a spectrum of immunopathology (for example, chronic aggressive hepatitis). The transplantation an alogy is chronic rejection or GVHD, which might be refractory to treatment with immunosuppression.
I O EC E, \ I BER 20 0 1 I VOLUME I
The reduced immunogenicity has bee n explained by the elimination of leukocyte s ubsets expressing MHC class II antigens or co-stimulatory molecules, such as B7 (CD8 0/86) -fo r examp le, donor dendritic cells·'. However, passe nger leukocytes might be immunoge n ic primilrily because they can migrate to lymphoid o rgans, whereas the fixed parench yma l ells ge nerall y cannot. The results of experiments w it.h fra ctio nated liver cell suspensio ns· z a nd with tumour cells lacking MH class 11 or so-called 'second si gnals'·' are consiste nt with this alternative hypothesi .
Immune igno raJl e ufhea rt all ografL'i bas been d efinitivel y s tudi ed dur in g t he past 5 yea rs in mu ta n t ( aly/ll ly) mit.: th at have nor mal T lymph ocytes .mct a spleen, but lack Peyer's patc hes and lymph nodes. Ca rd i<lc allogra fts drained into the circulation by vascular anasto mosis are indolently rejected, but when sp len ectomy is also performed, the hearts are permanently accepted". In addition to exemplifying immune ignora nce, the res ults con tradi cted the hi sto ri cal dogmas that the imm une res ponse to primarily vasculari ze d organs does no t require the presence of hos t lymp ho id orga ns, and that intragraft res ponses are g n e rated 'direc tl y' in the transplanted o rg<ln.
Collaborative mechanisms
With th . recog nit io n in the 19905 that th e key event in allograft a ceptance is cell migration and relocation ' l and that th e adaptive imm un e re ponse to lion-cytopathic organisms is determined by the m igratio n pa tterns of the path ugc n<o .
• " th e a n alogies be t> ... een infectiun and transpla ntat ion shown in BOX 1 were obvious. In essence, the do se, ki netics and loca li zation of an ti ge n in or out side lymph a ti c tissues regulate immune rcs ponsiven es:; or un res ponsiven ess not only agai ns t in fectio n and all og ra ft s, but also against tumou rs ,nd self. An ada ptive immune res ponse could then be viewed a, "a balance between pote nti ally reactive lymphocytes versus th e co m pos ition, qu a ntit y, kinetics, and distribution o f a ntigen (foreign or extralym pha tic self) within the host"I .
In th is co ntext, the pr . umably raTe Sto neLafferty graft r BOX 1 •• 1 is ignored beca use it contains so few leukocytes capable o f migrating to orga ni l.ed h os t lymph oid collections . By contrast, the t.ransp lan t outcomes (incl uding irre ve rsi ble a ut e rej ct io n; ROX I b) a re analogou . with those foil w ing spr adin g bl ood-bo rn e in fec tio ns by non-cytopat hi c microorganisms, in which variab le combination s of clonal exha ust io n-de letion and immune igno rance m ight result in degrees of respon sive ness an d non-re ponsiven ess. www .nature.com / reviews /lmmu nol At one extreme, clonal exhaustion induced by overwhelming numbers of leukocytes (BOX Ie) might allow unrestricted subsequent passage of donor cells between lymphoid and non-lymphoid compartments.
With less-complete deletion, cells that survive primary exposure to Iym phoid organs leave the blood and lymphoid tissues after 30--60 days and move to host non-parenchymal tissues and organs (for example, skin and heart3~-I6) or back to the transplanted organ· 7 • If sufficient numbers of these cells steadily em igrate from the extralymphatic sites to host lymphoid organs, the clonal exhaustion induced at the outset might be perpetuated with or without maintenance immunosuppression (BOX Id,e). If this traffic is minimal or irregular, however, the donor-specific responses might lead instead to acute (or chronic) organ rejection or permanent recipient sensitization; experimental variables that might tip the balance towards tolerance or rejection have been shown by Anderson and Matzinger S in mouse experiments. Even with the sustained presence of chimerism, the persistence of CTL and antibody responses might result in chronic rejection or GVHD (BOX 10_ What regulates alloimmune responses?
We have not discussed here the large body of historical' and recent work indicating the potential importance of immunoregulatory T cells and other changes in the host immune response for the mediation of immunity or tolerance. Particularly intense interest has focused on antigen-non-specific ,9 and antigen-specific T cells 50 that can downregulate both autoimmune and alloimrnune responses.
I\ i\T ll RE REVI E\ I' S I I MMUNOLOGY HOST VERSl:S GRAFT ( HVGl . Tho im mune reaction mounted bv the host a ga inst grafted tissue or an o rp n from the same species (alloresponse) o r a d iffere nt species (xenoresponse). 1 In addition, immature donor dendritic celJs might prolong organ allograft survivaPI in contrast to mature dendritic cells that efficientlyelicit rejection'!,
Immunoregulation by such subsets of special recipient or donor immune cells, alone or in concertS], could be important in future strategies of clinical transplantation. The same might be true of controlled changes in the host cylokine profile, or of the deliberate production of idiotypic or 'enhancing' antibodies. Elucidation of these frequently reported, but still poorly understood, regulation mechanisms will be necessary for their efficient exploitation. For now, we argue that the clinical and experimental observations in transplantation are most comprehensible in terms of antigen dose, localization and time during which the antigen is in organized lymphoid organs.
Clinical implications
From the historical perspective reviewed here, it is possible to analyse what has been, and what might be, accomplished in clinical transplantation. Except for Stone-Lafferty grafts, the persistence of donor haematopoietic cells (that is, chimerism) above some threshold required to maintain the clonal exhaustion induced at the outset is a necessary condition for long aLlograft survival. Reciprocal deletion of the characteristic double immune response of transplantation evolves spontaneously in some experimental organ transplant models (especially with leukocyte-rich liver allografts) 16, but immunosuppression is usually required to prevent one immune cell population from PERSPECTIVES destroying the other (that is, rejection or GVHD) long enough for the deletion to occur (FIG. 2) .
However, the chimerism-dependent clonal exhaustion, might be subverted by inappropriate post-transplant immunosuppression. Although over-immunosuppression can shut down clonal activation and prevent organ allograft rejection, which allows many of the donor leukocytes to survive and migrate to non-lymphoid sites, the further movement and pleiotropic immunological effects of these cells is unpredictable. Consequently, neither the presence nor quantity of microchimerism can be used to accurately guide managemen~U1..l'l.
By contrast, the donor-specific clonal expansion of the conventional BM recipient is reduced enough by prior cytoablation to be efficiently deleted by the donor leukocytes before these in fused cells are rejected, with minimal dependence on immunosuppression_ The widespread use of combined BM-organ transplantation in cytoablated recipients has been barred so far by the many parameters involved, of which the most restrictive is the need for a histocompatible donor for avoidance of GVHD. «Except for Stone-Lafferty grafts, the persistence of donor haematopoietic c lls (that is, chimerism). __ is a n ecessary condition for long allograft survival."
Compromise strategies between the radically different regimens of BM and organ transplantation have been extensively tested. The prototype compromise consists of donor BM-cell infusion after weakening the recipient's immune responsiveness in advance by non-myelotoxic cytoreduction (for example, with sublethal irradiation or anti-lymphoid antibody preparations), and then the use of low doses of immunosuppression after transplantation. Production of 'mixed macrochimerism' with acceptably few GVHD complications has been reported in rodents and inbred miniature pig organtransplant models, and in a small series of patients with haematological disorders given BM cells from one HLA haplotype-matched familial donors'J_ In simpler non-conditioning protocols first used clinically in 1976 by Monaco and co-workers", donor BM cells have been administered to human organ recipients treated with heavy (that is, potentially anti-tolerogenic) conventional immunosuppression. Despite a manifold increase in microchimerism in several trials, drug freedom has not been achieved except, apparently, in recent recipients of familial kidneys who were given megadoses of donor BM cells in Alunedabad, India 5 ; .
The value of donor pretreatment combined with minimal post-tranSplant immunosuppression has been suggested by the permanent donor-specific tolerance achieved without adjunct BM cells in 12 monkey kidney recipients that were conditioned with a depleting dose of immunotoxin and then treated with a 14-day course of deoxyspergualine afterward 56 • Although such short-term protocols regularly allow the induction of tolerance in rodents, they have not been used clinically. In the historical clinical experience, tolerance after human kidney transplantation has been rarely observed, and almost exclusively when the 'weak' immunosuppressant azathioprine was administered before and after transplantation, adding pred.nisone only for overt rejection 26 . Drug independence has been observed far more frequently after transplantation of the liver, but in large numbers only when the original immunosuppression was with azathioprine-based regimens that included pretreatment with ALG, or in patients who were weaned from tacrolimusi:·.;s .
It might be possible to achieve drug-free tolerance with organs less well-endowed with leukocytes than the liver, using a clinical protocol of host conditioning with ALG and minimal post-transplant immunosuppression that was introduced in 1966 (REF. 27 ), but ultimately abandoned. Armed with modem drugs, including powerful anti-lymphoid antibody agents, a markedly reduced need for early and maintenance immunosuppression ( including nearly complete elimination of prednisone) has been reported from several centres. In Cambridge (United Kingdom), CaIne et al. 59 have treated cadaver kidney recipients with a few perioperative doses of a humanized depleting anti-CD 52 monoclonal antibody (T and B cell plus monocyte reactive), followed by low-maintenance doses of cyclosporine alone.
Conclusion
Although much of the progress in transplantation has depended on the development of increasingly potent immunosuppressants, elucidation of the mechanisms of allograft acceptance has set the stage for more d.iscriminating use of these agents. Theoretically, it 238 I D EC EM BER 2001 I VOLUME 1 «Theoretically, it should be possible in the futur to apply immunosuppression and/or immunostimulation in just the right balanced way to either achieve immunolgical indifference (ignorance ) . .. or to obtain stable drug-free and antigen-dependent T-cell exhaustion and chimerism. ') should be possible in the future to apply immunosuppression and/or immunostimu-!ation in just the right balanced way to either achieve immunological indifference (ignorance) in some cases, particularly with hormone-producing cells and small organs, or to reliably achieve the perfect equilibrium of mutual immune reactivity and T-cell exhaustion or to obtain stable drug-free and antigendependent T-cell exhaustion and chimerism.
A universally applicable protocol for organ transplantation will probably be some modernized version of the empirically derived flexible formulas that originally made organ transplantation a practical patient service.
The key therapeutic principles are: first, recipient pretreatment using antibodies or other modalities for conditioning; and second, minimal short-term immunosuppression after transplantation. The value of adjunct donor haematolymphopoietic cells should then become apparent. 
